ROGER CRYSTAL

CIK 1656633 · Chief Executive Officer · last filed 2026-06-15

ROGER CRYSTAL is a Chief Executive Officer who has filed 24 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for DFTX, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.08M

Companies

3

Total Filings

24

Lifetime Open-Market Net

-$2.05M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
DFTX	Director	24,289	$44.39	$1.08M	$0	1	2026-06-15
Definium Therapeutics, Inc. (MNMD) Delisted	Director	19,623	$15.00	$294.3K	$0	4	2025-06-16
OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Chief Executive Officer	6,667	$20.65	$137.7K	-$2.05M	18	2023-03-03

Recent Filings

24 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-06-15	DFTX	Grant (A)	+4,666	$0	EDGAR
2025-06-16	Definium Therapeutics, Inc. (MNMD) Delisted	Grant (A)	—	$0	EDGAR
2024-06-12	Definium Therapeutics, Inc. (MNMD) Delisted	Grant (A)	—	$0	EDGAR
2023-06-23	Definium Therapeutics, Inc. (MNMD) Delisted	Grant (A)	+13,671	$0	EDGAR
2023-03-03	OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Mixed	−80,439	-$1.74M	EDGAR
2023-01-31	OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Sell (S)	−1,358	-$27.5K	EDGAR
2023-01-09	OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Sell (S)	−1,183	-$23.9K	EDGAR
2023-01-05	OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Sell (S)	−5,029	-$101.6K	EDGAR
2022-08-15	Definium Therapeutics, Inc. (MNMD) Delisted	Grant (A)	+89,286	$0	EDGAR
2022-07-15	OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted	Sell (S)	−2,246	-$25.0K	EDGAR

Showing 1–10 of 24

Page 1 of 3 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.